 This is Money |
MARKET REPORT: Skyepharma in a jam over asthma drug
This is Money … was run by its controversial founder Ian Gowrie Smith, who then had a history of over-promising and under-delivering, the City was up in arms after he announced a shock deeply-discounted £35m rights issue to develop Flutiform, its asthma treatment. … SkyePharma's Asthma Treatment Faces European Approval Delay; Shares Fall SkyePharma hit with European delay on Flutiform app SkyePharma lung drug faces European approval delay |
View full post on asthma – Google News